Table 2.

Baseline characteristics and changes after 6 months in the myoinositol and metformin group.

Intervention	Myoinositol (n = 14)			Metformin (n = 12)
Time	Baseline	6 Months	Δ p	Baseline	6 Months	Δ p	Δ vs. Δ p
SF-36
Physical functioning	90 (75;95)	90 (80;95)	0.14	90 (85;95)	95 (85;100)	0.16	0.78
RPH	88 (50;100)	100 (50;100)	0.57	100 (75;100)	100 (50;100)	0.29	0.25
REP	100 (0;100)	100 (33;100)	0.58	100 (50;100)	100 (17;100)	0.28	0.29
Energy/fatigue	50 (35;60)	53 (30:65)	0.59	40 (25;65)	48 (30;73)	0.61	0.22
Emotional well-being	74 (60;84)	80 (52;84)	0.57	72 (58;84)	70 (52:84)	0.32	0.31
Social functioning	59 (45;80)	69 (38;80)	0.92	53 (36;73)	64 (40;79)	0.43	0.55
Pain	58 (45;90)	68 (55;90)	0.61	74 (68;95)	69 (68;90)	0.52	0.50
General health	65 (50;80)	63 (35;75)	0.25	58 (38;80)	68 (38;78)	0.42	0.17
MDI
Score	11 (9;20)	10 (7;22)	0.92	13 (5;29)	15 (6;27)	0.87	1.0

Values are shown as medians (IQR, interquartile range, 25%; 75%). SF-36: Short Form Health Survey, RPH: role limitations due to physical health, REP: role limitations due to emotional problems, MDI: Major Depression Inventory. Δ p: p-value for Δ value (6–0 months), Δ vs. Δ p: p-value for comparison of the Δ values.